Bravo Multinational owns and operates gaming assets in Latin America. It currently generates revenue from 150 gaming machines in Nicaragua and expects to reach a $3.5 million annual revenue run rate by 2017. The company is expanding operations to include two gaming licenses in El Salvador and plans to place gaming machines in Colombia through a leasing partnership. Bravo highlights Latin America's growing economies and expanding middle class as positive market trends for its business. It is also exploring opportunities to diversify beyond gaming and add to its bottom line earnings.
What does the rest of 2016 hold for the innovation economy? SVB Analytics' State of the Markets Report provides a summary of key market indicators impacting the innovation economy, including venture capital funding and valuation trends, crossover investor activity, and what’s ahead for the second half of 2016.
Recruiter.com Group Inc. (OTCQB: RCRT) is disrupting the recruiting and staffing industry by aggregating the small and independent recruiters under a common platform, giving them access to large enterprise customers and advanced technologies.
Silicon Valley Bank’s Trends in Healthcare Investments and Exits report analyzes the fundraising, investment, M&A and IPO activity of private, venture-backed biopharma, medical device and diagnostic/tools companies. Report author Jon Norris also gives his annual forecast of what’s likely to happen in 2016.
What does the rest of 2016 hold for the innovation economy? SVB Analytics' State of the Markets Report provides a summary of key market indicators impacting the innovation economy, including venture capital funding and valuation trends, crossover investor activity, and what’s ahead for the second half of 2016.
Recruiter.com Group Inc. (OTCQB: RCRT) is disrupting the recruiting and staffing industry by aggregating the small and independent recruiters under a common platform, giving them access to large enterprise customers and advanced technologies.
Silicon Valley Bank’s Trends in Healthcare Investments and Exits report analyzes the fundraising, investment, M&A and IPO activity of private, venture-backed biopharma, medical device and diagnostic/tools companies. Report author Jon Norris also gives his annual forecast of what’s likely to happen in 2016.
Finding Your 'ESG Mindset' with Invest EuropeNavatar
Experts from PAI Partners, KPMG and APG Asset Management showcase Invest Europe’s new ESG due diligence questionnaire, and explain how it helps private equity managers meet investors’ growing calls for responsible investment to become a central pillar of their investment strategies.
Business and Professional CommunicationsDave Hogan
A basic primer on business and professional communication tips, including tips for proper use of cellphones and email. Includes recommendations for personal and business etiquette.
Keeping reserves for a “rainy day” is a good practice for all nonprofit institutions, but how much should your organization set aside? A percentage of annual budget? Three-to-six months? Our answer is: it depends. Each nonprofit is unique and can experience distinct unexpected circumstances that may affect its long-term financial health.
This session, led by mark Murphy of Raffa Wealth Management, will focus on how to conduct a risk assessment that will assist your nonprofit in quantifying financial risks and opportunities. Once completed, this risk assessment aims to assist in finding the appropriate reserve level for your unique organization.
Whether you are in the initial phases of creating your nest egg or revaluating longstanding reserve levels, this session is for you.
Based in Ann Arbor, Michigan, Zomedica is a veterinary health company creating diagnostic and therapeutic products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. With modest cash burn and a strong balance sheet, including $142.4 million cash and cash equivalents as of June 30, 2023, Zomedica is well-positioned to fund both organic growth and acquisitions.
Dócola is a social good organization with the only free care communication platform that consolidates thousands of free and low-cost patient education resources from the leading nonprofit, government, and commercial organizations in one marketplace. Plus, you can easily create and upload your own resources.
INNO HOLDINGS INC. is an innovative building-technology company with a mission to transform the construction industry with our proprietary cold-formed steel- framing technology and other building innovations
Everything Blockchain builds platforms of trust for the modern enterprise and is on a mission to ensure every organization has access to the tools and platforms that enable them to manage, store, and protect data without the cost and complexity that holds them back today. The Company’s patented advances in engineering deliver the essential elements needed for real-world business use: speed, security, and efficiency. Everything Blockchain’s current business lines include: EB Advise, Build DB and EB Control.
ASP Isotope is an isotope enrichment company utilizing technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses. Many of these elements are unsuitable for enrichment using traditional methods such as centrifuges. The Company’s initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries.
MDNA Life Sciences is a pioneer in the science of mitochondrial DNA. It’s our mission to create an extensive portfolio of proprietary tests that dramatically improve diagnosis, treatment, prognosis and monitoring. Putting an end to the unnecessary surgical procedures, pain and uncertainty that affect patients across the world.
Digital Ally, Inc. is a diversified holding company with operations in video solution technology, human and animal health protection products, healthcare revenue cycle management, ticket brokering and marketing, and event production. The Company pursues an acquisition strategy that targets organizations with positive earnings, strong growth potential, innovation, and operational synergies. To maximize long-term shareholder value, Digital Ally intends to spin-off its ticketing and entertainment business lines into a separate public company in 2023. The spin-off will create two optimized, tech-driven public companies with strong growth opportunities and operating metrics.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program.
Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The Company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and is on track to launch this new product line in Q4 2023. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US.
Aditxt is a global innovation company focused on discovering and developing precision medicine innovations and deploying them into high-performing businesses. Aditxt’s diverse innovation portfolio includes: Adimune™, Inc., developing and designing a new class of therapeutics for retraining the immune system to address organ rejection, autoimmunity, and allergies; Adivir™, Inc., focused on identifying, developing and commercializing new ways to treat infectious diseases; and Pearsanta™, Inc., offering convenient, rapid, personalized, and high-quality lab testing —anytime and anywhere at its CLIA certified and CAP accredited clinical laboratory based in Richmond, VA.
1847 Holdings LLC, a publicly traded diversified acquisition holding company, was founded by Ellery W. Roberts, a former partner of Parallel Investment Partners, Saunders Karp & Megrue and Principal of Lazard Freres Strategic Realty Investors. EFSH's investment thesis is that capital market inefficiencies have left the founders and/or stakeholders of many small business enterprises and lower-middle market businesses with limited exit options, despite the intrinsic value of their business. Given this dynamic, EFSH can consistently acquire "solid" businesses for reasonable multiples of cash flow and then deploy resources to strengthen the infrastructure and systems to improve operations. These improvements may lead to a sale or IPO of an operating subsidiary at considerably higher valuations than the purchase price (as successfully demonstrated with the mid-2020 IPO of 1847 Goedeker on the NYSE American) and/or alternatively, an operating subsidiary may be held in perpetuity and contribute to EFSH's ability to pay regular and special dividends to shareholders.
Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The Company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and is on track to launch this new product line in Q4 2023. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US.
SPI Energy is a global renewable energy company and provider of solar storage and electric vehicle (EV) solutions that was founded in 2006 in Roseville, California and is headquartered in McClellan Park, California. The Company has three core divisions: SolarJuice which has solar wholesale distribution, as well as residential solar and roofing installation and solar module manufacturing (Solar4America & SEM Wafertech), SPI Solar and Orange Power which operates a commercial & utility solar division, and the EdisonFuture/Phoenix Motor EV division. SolarJuice is the leader in renewable energy system solutions for residential and small commercial markets and has extensive operations in the Asia Pacific and North America markets. The SPI Solar commercial & utility solar division provides a full spectrum of EPC services to third party project developers, and develops, owns and operates solar projects that sell electricity to the grid in multiple regions, including the U.S., U.K., and Europe. Phoenix Motor is a leader in medium-duty commercial electric vehicles, and is developing EV charger solutions, electric pickup trucks, electric forklifts, and other EV products. SPI maintains global operations in North America, Australia, Asia and Europe and is also targeting strategic investment opportunities in fast growing green energy industries such as battery storage, charging stations, and other EVs which leverage the Company's expertise and substantial solar cash flow.
BullFrog AI is a technology enabled drug development company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University and J. Craig Venter Institute, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may have otherwise not received the therapies they need.
BullFrog AI is a technology enabled drug development company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University and J. Craig Venter Institute, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may have otherwise not received the therapies they need.
BioVie is a clinical-stage company developing what it believes will be transformative therapies to overcome unmet medical needs in neurodegeneration and liver disease. The Company is developing NE3107 for Alzheimer’s (AD) and Parkinson’s (PD) and BIV201 for refractory ascites and HRS-AKI.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program.
Genetic Technologies is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GENE offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products.
Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and non-alcoholic beverage brands including Copa di Vino wines by the glass, SALT naturally flavored tequilas, Pulpoloco Sangria, and TapouT performance hydration and recovery drinks and TapouT Cognitive Energy Drink. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution.
Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and non-alcoholic beverage brands including Copa di Vino wines by the glass, SALT naturally flavored tequilas, Pulpoloco Sangria, and TapouT performance hydration and recovery drinks and TapouT Cognitive Energy Drink. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution.
2. This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995. All statements pertaining to future financial and/or operating results, future events, or
future developments involving Sack Lunch Productions may constitute forward-looking statements. The
statements may be identified by words such as “expect,” “look forward to,” “anticipate,” “intend,” “plan,”
“believe,” “seek,” “estimate,” “will,” “project,” or words of similar meaning. Such statements are based on the
current expectations and certain assumptions of Bravo Multinational’s management, of which many are
beyond control. These are subject to a number of risks, uncertainties, and factors, including but not limited to
those described in disclosures, in particular in the chapter Risks in the Annual Report. Should one or more of
these risks or uncertainties materialize, or should underlying expectations not occur or assumptions prove
incorrect, actual results, performance, or achievements of Bravo Multinational may (negatively or positively)
vary materially from those described explicitly or implicitly in the relevant forward-looking statement. Bravo
Multinational neither intends, nor assumes any obligation, to update or revise these forward-looking
statements in light of developments which differ from those anticipated.
This presentation includes supplemental financial measures that are or may be non-GAAP financial measures.
These supplemental financial measures should not be viewed in isolation or as alternatives to measures of
Bravo Multinational net assets and financial positions or results of operations as presented in accordance
with IFRS in its Consolidated Financial Statements. Other companies that report or describe similarly titled
financial measures may calculate them differently. Due to rounding, numbers presented throughout this and
other documents may not add up precisely to the totals provided and percentages may not precisely reflect
the absolute figures.
2016 Bravo Multinational | www.bravomultinational.com
Forward-Looking Statement
3. Owns and develops gaming assets in Latin America
2016 Bravo Multinational | www.bravomultinational.com
Overview
Exchange: Ticker OTCQB: BRVO
Recent Price $0.02
Shares Outstanding 341.3 million
Float 153.2 million
Market Cap $6.49 million
Currently generating revenue primarily from Nicaraguan
operations
Managua, Nicaragua San Andreas, ColumbiaSan Salvador, El Salvador
4. • Experienced management team
• Deep relationships across Latin America
• In-depth understanding of regulatory, political and social issues
• Only “TURN-KEY” provider with 10+ years infrastructure and
operational expertise in Latin America
2016 Bravo Multinational | www.bravomultinational.com
Game Touch Marketing Partnership
NET PROFIT AFTER EXPENSES
5. • 150 machine owned (500 committed)
• Buy machines for $4500, can resell
(market rate $7,000)
• Earn 50% of take every month from
machines in operation
2016 Bravo Multinational | www.bravomultinational.com
Current Operations – Managua, Nicaragua
Financial Performance:
• Generated $370,000 in first 100 days
• Estimated to reach $3.5M revenue
run-rate in 2017
• Forecasting 15%-20% growth annually
6. 2016 Bravo Multinational | www.bravomultinational.com
Expanding Operations in El Salvador and Columbia
San Salvador, El Salvador:
• Own operational rights to two (2) land-based
“Gaming and Betting Licenses”
• Bravo receives monthly royalty revenue
• Expect to add two (2) additional licenses in 1Q17
San Andreas, Columbia:
• Own $2.4 million worth of gaming
machines
• Working with Leasing Partner to
place machines
7. 2016 Bravo Multinational | www.bravomultinational.com
Market Opportunity
Attractive Market Trends in Latin America
• High-growth economies
• Expanding middle-class
• Large investment flows into region
Exploring Opportunities Beyond Gaming Industry
• Initially focused on Nicaragua
• Add to bottom-line earnings & shareholder value
8. 2016 Bravo Multinational | www.bravomultinational.com
Management Team & Key Affiliates
Senior Executives
Corporate Development Consultants Professional Associates & Affiliates
Paul Parliament CEO, President, Chairman
Martin Wolfe CPA CA CFO, Treasurer
Douglas Brooks Vice President, Director
Richard Kaiser Corporate Secretary, Director
Julios Kosta Corporate Development
Jack Frydman Corporate Development
Allen Simon Corporate Advisor
Norman T. Reynolds
Law, P.C.
Corporate Attorney
RedChip Companies Full Service IR Firm
YES International Full Service IR Firm
Scrudato & Co., PA CPA
Transfer Online, Inc. Stock Transfer Agent
9. 2016 Bravo Multinational | www.bravomultinational.com
Investment Highlights
• Established gaming operations in Latin America
• Growing business in a growing market
• Exploring expansion & diversification opportunities
• Strong cash flow models
• Low overhead & expenses
• Less than $400K in debt
• $3.5M revenue run-rate expected in 2017
• 15%-20% annual growth forecast
10. Investors can purchase machines for approx. $7,000 (US)
• Ave. payback: $265 per machine
• Machine pays for itself in 2.5 years
• Investors keep 50% of the “take” (profit)
2016 Bravo Multinational | www.bravomultinational.com
Game Touch Opportunity
NET PROFIT AFTER EXPENSES
11. Bravo Multinational, Inc.
(OTCQB: BRVO)
Bravo Multinational, Inc.
590 York Road, Unit #3
Niagara On The Lake,
Ontario, L0S 1J0
USA: 1-716-803-0621
Canada: 1-905-684-1515
info@bravomultinational.com
GameTouch, LLC
600 Parkview Drive, Suite #921
Hallandale, FL 33009
Toll-Free: 1-855-636-8825
info@gametouchllc.com
Investor Relations
RedChip Companies, Inc.
Michael Sully, Specialist
USA: 1-407-644-4256
michael@redchip.com
www.bravomultinational.com www.gametouchllc.com